Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of YP-18 (tazobactam/piperacillin) for febrile neutropenia
jRCT2080221686Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of piperacillin + tazobactam in febrile neutropenia (FN), Non-hematologic malignancy and hematopoietic malignancies, sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
piperacillin + tazobactam
03
Conditions
febrile neutropenia (FN)Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2080221686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221686.